


COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/902,556	07/10/2001	Romano Deghenghi	87264-200

28765
WINSTON & STRAWN
200 PARK AVENUE
NEW YORK, NY 10166-4193

CONFIRMATION NO. 7188

FORMALITIES LETTER



OC000000006834574

Date Mailed: 10/02/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:


- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 1 - ATTORNEY/APPLICANT COPY



1-10-02

GP 1646/ BPC Seq
#4

EXPRESS MAIL NO.: EL 803 540 253 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Romano DEGHENGI

Application No.: 09/902,556

Group Art Unit: 1646

Filed: July 10, 2001

Examiner: To Be Assigned

For: GHRELIN ANTAGONISTS

Attorney Docket No.: 87264-200

**RESPONSE TO NOTICE TO COMPLY WITH
REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

RECEIVED
JAN 17 2001
TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to a Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures, mailed October 2, 2001 in connection with the above-identified application, Applicants submit herewith a Sequence Listing in paper and computer readable form pursuant to 37 C.F.R. § 1.821(c) and (e), respectively.

I hereby state that the content of the paper and computer readable copies of the Substitute Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

I hereby state that the submission herein, filed in accordance with 37 C.F.R. § 1.821(g) does not include new matter.

Date: 10/25/01

Respectfully submitted,
Allan A. Fanucci 30,256
Allan A. Fanucci Reg. No.

WINSTON & STRAWN
200 Park Avenue
New York, New York, 10166
(212) 294-3311

DATE CANCELLED

SEQUENCE LISTING



#4

<110> Deghenghi, Romano

<120> GHRELIN ANTAGONISTS

<130> 87264-200

<140> US 09/902,556

<141> 2001-07-10

<150> US 60/220,178

<151> 2000-07-13

<160> 4

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> An Artificial Sequence which is a synthetic variation of known Ghrelin peptides which were isolated in the stomach by a distinct cell type in rats and humans.

<220>

<221> MOD_RES

<222> (3)..(3)

<223> Octanoyl ester attached to serine residue

<220>

<221> MISC_FEATURE

<222> (5)..(5)

<223> X is OH, NH₂, Leu-Ser-Pro-Glu-X, or Ala-Lys-Leu-Gln-Pro-Arg-B where B is OH or NH₂.

<400> 1

Gly Ser Ser Phe Xaa

1

5

RECEIVED
JAN 17 2001
TECH CENTER 1600/2900

<212> PRT

<213> Artificial Sequence

<220>

<223> An Artificial Sequence which is a synthetic variation of known Ghrelin peptides which were isolated in the stomach by a distinct cell type in rats and humans.

<220>

<221> MOD_RES

<222> (3)..(3)

<223> An octanoyl ester is attached to the serine residue

<400> 2

Gly Ser Ser Phe Leu Ser Pro Glu
1 5

<210> 3

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> An Artificial Sequence which is a synthetic variation of known Ghrelin peptides which were isolated in the stomach by a distinct cell type in rats and humans.

<220>

<221> MOD_RES

<222> (3)..(3)

<223> An octanoyl ester is attached to the serine residue

<400> 3

Gly Ser Ser Phe Leu Ser Pro Glu Ala Lys Leu Gln Pro Arg
1 5 10

<210> 4

<211> 4

<212> PRT

<220>

<221> MOD_RES

<222> (3)..(3)

<223> An octanoyl ester is attached to the serine residue

<400> 4

Gly Ser Ser Phe

1